Karen Guidry
Primary Care · Atlanta, GANPI 1346864725
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations.
Across 180 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$480
- Novo Nordisk$315
- Lilly USA, LLC$306
- Novartis$251
- Amgen$237
- Actelion Pharmaceuticals US, Inc.$220
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,335100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $480 |
| Novo Nordisk | 19 | $315 |
| Lilly USA, LLC | 17 | $306 |
| Novartis | 13 | $251 |
| Amgen(2 entities) | 14 | $237 |
| Actelion Pharmaceuticals US, Inc. | 9 | $220 |
| GSK | 10 | $159 |
| AstraZeneca | 9 | $147 |
| Pfizer | 5 | $122 |
| Xeris Pharmaceuticals, Inc. | 5 | $111 |
| Merck | 6 | $100 |
| Shield Therapeutics Inc | 4 | $94 |
| Exact Sciences | 4 | $81 |
| Viiv Healthcare Company | 3 | $79 |
| Dexcom, Inc. | 4 | $74 |
| Boehringer Ingelheim | 3 | $71 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $70 |
| Sumitomo Pharma America, Inc. | 3 | $52 |
| Astellas Pharma US Inc | 2 | $46 |
| Inspire Medical Systems, Inc. | 1 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Gilead | 2 | $37 |
| Abiomed | 1 | $28 |
| Corcept Therapeutics | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Bayer | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
How this compares
$3,347 in reported general payments places this provider in the 85th percentile of 235 primary care providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $43,800 |
| JardianceEmpagliflozin | 20 | $24,802 |
| MounjaroTirzepatide | 16 | $20,341 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $7,459 |
| Atorvastatin Calcium | 167 | $1,932 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $1,117 |
| Rosuvastatin Calcium | 72 | $923 |
| Fluticasone Propionate | 69 | $919 |
| Amlodipine Besylate | 190 | $832 |
| Ezetimibe | 44 | $547 |
| Losartan Potassium | 43 | $508 |
| Potassium Chloride | 29 | $482 |
| Hydralazine Hcl | 29 | $461 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 20 | $410 |
| Gabapentin | 43 | $397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $315 | $43,80036 claims |
| Boehringer IngelheimJardiance | $71 | $24,80220 claims |
| Lilly USA, LLCMounjaro | $306 | $20,34116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 235 primary care providers in Georgia.
Other primary care in Atlanta
- Erin EverettAtlanta$7K
- Erin BartonAtlanta$6K
- Natasha WilliamsonAtlanta$5K
- Lauren BolleAtlanta$4K
- Caroline ClaarAtlanta$3K
- Pamela TurkDouglas$15K
- Morgan JonesLawrenceville$14K
- Jessi HaleColumbus$13K
- Meredith CarrAugusta$12K
- Ashtyn ZaryckiSavannah$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.